TL;DR
This study employs a multi-omics approach, combining network pharmacology and weighted gene co-expression network analysis (WGCNA), to unravel the molecular mechanisms of Changweiqing (CWQ), a traditional Chinese medicine, in treating colorectal cancer (CRC). The research identifies CDKN2A as a key target of CWQ, suggesting that CWQ's anti-cancer effects are mediated through its influence on cell cycle regulation.
What Problem Does This Paper Address?
Colorectal cancer (CRC) remains a significant global health challenge due to its heterogeneity and metastatic potential, making effective treatment difficult. While traditional Chinese medicine (TCM) offers promising therapeutic avenues, the precise molecular mechanisms of many TCM formulas, like Changweiqing (CWQ), are not fully understood. CWQ is a known formula for gastrointestinal diseases, and preliminary studies suggest it can inhibit CRC growth. However, a comprehensive understanding of its targets and pathways is needed to support its clinical application. This paper aims to bridge this knowledge gap by using advanced bioinformatics techniques to elucidate CWQ's mechanism of action against CRC.
Methods
The study integrates several powerful bioinformatics and experimental techniques:
- Network Pharmacology: This approach was used to identify the bioactive components of CWQ and their potential therapeutic targets. Databases like TCMSP and HERB were utilized to collect CWQ ingredients, and SwissTargetPrediction was employed to predict their targets.
- Weighted Gene Co-expression Network Analysis (WGCNA): WGCNA was applied to the TCGA-COAD dataset to identify modules of highly correlated genes associated with CRC progression. This method helps in uncovering gene networks that are functionally related to the disease.
- Differential Gene Expression Analysis: Standard methods were used to identify differentially expressed genes (DEGs) between CRC and normal tissues from the TCGA-COAD dataset.
- Database Integration: Multiple public databases (DisgeNET, GeneCards, MalaCards, OMIM, CTD) were used to gather a comprehensive list of CRC-related genes.
- Protein-Protein Interaction (PPI) Network Analysis: STRING database and Cytoscape software were used to construct and analyze PPI networks of the identified core targets, helping to pinpoint key regulatory nodes.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Enrichment Analysis: These analyses were performed to understand the biological functions and pathways associated with the identified targets.
- Molecular Docking: AutoDock Vina was used to predict the binding affinity between key CWQ components and the identified target protein (CDKN2A), providing insights into their molecular interactions.
- In Vitro Experiments: Cell viability assays (CCK-8) and flow cytometry were conducted using human CRC cell lines (HT-29 and SW-480) treated with quercetin (a major CWQ component) to validate its effects on cell proliferation and cell cycle. qRT-PCR was used to assess the expression of key cell cycle regulatory genes.
Datasets
The study utilized several publicly available datasets:
- The Cancer Genome Atlas (TCGA) - Colon Adenocarcinoma (COAD) cohort: This dataset provided gene expression profiles and clinical information for CRC patients, used for differential expression analysis and WGCNA.
- Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP): Used for collecting bioactive components of CWQ.
- HERB database: Also used for collecting bioactive components of CWQ.
- SwissTargetPrediction platform: Used for predicting drug targets.
- DisgeNET, GeneCards, MalaCards, Online Mendelian Inheritance in Man (OMIM), and Comparative Toxicogenomics Database (CTD): These databases were used to retrieve CRC-related genes.
- Protein Data Bank (PDB): Used to obtain the 3D crystal structure of CDKN2A.
- PubChem database: Used to obtain the 3D structures of small molecules (CWQ components).
- Human Protein Atlas (HPA) database: Used to show protein subcellular localization.
- Gene Expression Profiling Interactive Analysis (GEPIA) database: Used to analyze the relationship between gene expression and patient survival/stage.
- University of Alabama at Birmingham CANcer data analysis Portal (UALCAN): Used to analyze gene methylation levels.
- GeneMANIA database: Used to analyze functionally similar genes.
Key Insights and Ideas
- CDKN2A as a Central Target: The study strongly implicates CDKN2A as a pivotal target of CWQ in CRC treatment. This identification is a significant outcome, providing a specific molecular focus for CWQ's action.
- Multi-Target, Multi-Pathway Action: CWQ's therapeutic effect is not attributed to a single component or pathway but rather a complex interplay of multiple bioactive ingredients targeting various biological processes, particularly cell cycle regulation.
- Synergy of Bioinformatics Approaches: The combination of WGCNA and network pharmacology proved effective in reducing the complexity of TCM and identifying a core set of crucial targets, overcoming a common challenge in TCM research.
- Quercetin's Role: Quercetin, a major component of CWQ, was experimentally validated to inhibit CRC cell viability and induce G0/G1 cell cycle arrest, supporting its role in CWQ's anti-cancer effects.
- CDKN2A and Prognosis Link: The research highlights a significant correlation between high CDKN2A expression and poor prognosis in CRC patients, further solidifying its importance in the disease.
Key Results
- Identification of 14 Core Genes: Through the integration of DEGs, WGCNA, and public databases, 14 common genes were identified as potential targets of CWQ in CRC.
- CDKN2A's Prognostic Significance: High expression of CDKN2A was significantly associated with shorter overall survival and advanced clinical stage in CRC patients. CDKN2A promoter was also found to be hypermethylated in CRC.
- Molecular Docking Insights: Key CWQ components, including quercetin and luteolin, showed good binding affinity with CDKN2A, suggesting direct interaction. Quercetin, for instance, formed multiple hydrogen bonds with CDKN2A residues.
- Quercetin's In Vitro Effects: Quercetin treatment significantly inhibited CRC cell viability and induced G0/G1 phase arrest in HT-29 and SW-480 cells. It also modulated the expression of key cell cycle regulators (e.g., decreased CCND1, CCNE1, CDK2; increased CDK4, p21).
Limitations and Future Work
The authors acknowledge several limitations:
- Limited Exploration of Other Components: The study primarily focused on quercetin's in vitro effects, with the biological functions of other CWQ components in CRC cells not being fully explored.
- Missing Functional Assays: The research did not investigate CWQ's effects on CRC cell migration, invasion, or chemotherapy sensitivity, which are critical aspects of cancer progression.
- Need for Preclinical Validation: The findings require further validation in animal models and preclinical models (e.g., organoids) to provide more robust evidence for clinical application.
Future work should focus on elucidating the roles of other CWQ components, conducting comprehensive functional assays, and validating these findings in more complex biological systems.
Summary updated